Technology
Health
Pharmaceutical

CTI BioPharma

$1.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
+$0.01 (0.99%) After Hours

Why Robinhood?

You can buy or sell CTI BioPharma and other stocks, options, ETFs, and crypto commission-free!

About

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. Read More The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Employees
46
Headquarters
Seattle, Washington
Founded
1991
Market Cap
58.57M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
399.75K
High Today
$1.03
Low Today
$0.98
Open Price
$1.02
Volume
124.74K
52 Week High
$5.36
52 Week Low
$0.6001

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
US
North America

News

PR NewswireMar 13

CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018. "The Company is focused on advancing its development program of pacritinib for the treatment for myelofibrosis patients with severe thrombocytopenia in the United States and Europe in 2019," commented Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "Following the previously-announced completion of full e...

171
Markets InsiderMar 13

EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q4 Earnings Report

(RTTNews) - Below are the earnings highlights for CTI BioPharma Corp. (CTIC): -Earnings: $0.85 million in Q4 vs. -$14.27 million in the same period last year. -EPS: $0.01 in Q4 vs. -$0.33 in the same period last year. -Revenue: $14.11 million in Q4 vs. $0.46 million in the same period last year....

74
PR NewswireMar 12

CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19

SEATTLE, March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central. Presentation details: Event: Oppenheimer's 29th Annual Healthcare Conference Date: Tuesday, Mar. 19 Time: 4:30 p.m. EDT The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ct...

5

Earnings

-$0.33
-$0.21
-$0.09
$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.28 per share
Actual
$0.01 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.